Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 4,634 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Interventions: Apixaban, Aspirin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more

Conditions: Extraocular Retinoblastoma
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Radiation Therapy, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more

Conditions: Agitation
Interventions: Quetiapine, Haloperidol, Lorazepam, Cogentin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions: Color fundus photography, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study; Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 103
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more

Conditions: Metastatic HER2-positive Breast Cancer
Interventions: Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 34 more

Conditions: Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
Interventions: Modified Measles Virus, Modified Measles Virus Lumbar Puncture; Biological
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 12 Months to 39 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Decision Support System, Outcome
Interventions: Routine care, AFM; Procedure · Device
Lead sponsor: Assistance Publique - Hôpitaux de Paris; Other
Eligibility: 18 Years and older
Enrollment: 2,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Irvine, California • Los Angeles, California

Conditions: Lung Cancer
Interventions: smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care; Behavioral · Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 175
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 115 more

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 365
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more

Conditions: Cardiothoracic Surgery
Interventions: HEMOBLAST Bellows, FLOSEAL; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 4
States / cities: Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: Osteosarcoma, Leukemia, Lymphoma
Interventions: glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin; Drug
Lead sponsor: BTG International Inc.; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Afrezza; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more

Conditions: Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: zoledronic acid, quality-of-life assessment; Drug · Procedure
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 55
States / cities: Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more

Conditions: Systemic Sclerosis
Interventions: Pirfenidone; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more

Conditions: Acute Myelogenous Leukemia
Interventions: CD33CART autologous, CD33CART allogeneic; Biological
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 1 Year to 35 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2039
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Bethesda, Maryland + 3 more

Conditions: Papillary Thyroid Cancer
Interventions: Molecular Analysis for Thyroid Resection; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clostridium Difficile Infection Recurrence
Interventions: Full Spectrum Microbiota, Placebo; Drug
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 54
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more

Conditions: Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions: Prednisone; Drug
Lead sponsor: John Levine; Other
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 45 Years to 99 Years
Enrollment: 12,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 140
States / cities: Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more

Search by objective public record fields.

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Assisted Fluid Management (AFM) System and Postoperative Outcome After High-risk Abdominal Surgery

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Pediatric GVHD Low Risk Steroid Taper Trial

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity